drug
sparsentan
Marketedupdated 3mo agoby $TVTX Travere Therapeutics, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for iga glomerulonephritis and 3 investigational indications.
all catalysts(5)
approval · 5
Feb 17, 2023
approval
$TVTX63.14+1.60%
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Oct 18, 2023
approval
$TVTX63.14+1.60%
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Sep 5, 2024
approval
$TVTX63.14+1.60%
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Aug 27, 2025
approval
$TVTX63.14+1.60%
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Apr 13, 2026
approval
$TVTX63.14+1.60%
FILSPARI (SPARSENTAN) — FDA approval
sparsentan
→
Trials studying sparsentan
- phase1Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
- phase3A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- phase3Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- phase4Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
- phase2Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- phase2A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
- phase2ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
- phase2Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 17, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Mar 29, 2030method-of-use (U-3993)US 99934613.6y
- Mar 29, 2030method-of-use (U-3993)US 99934613.6y
FDA exclusivities (6)
- Sep 5, 2031ODE-493Orphan Drug (7y)
- Sep 5, 2031ODE-493Orphan Drug (7y)
- Feb 17, 2030ODE-389Orphan Drug (7y)3.5y
- Feb 17, 2030ODE-389Orphan Drug (7y)3.5y
- Feb 17, 2028NCENew Chemical Entity (5y)1.5y
- Feb 17, 2028NCENew Chemical Entity (5y)1.5y
News(1)
- Travere pays Everest $112M upfront to grow rare kidney disease pipelineTravere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…endpoints · 2mo ago
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that